Rationale, aims, and objectives: The Ghent Older People's Prescriptions community Pharmacy Screening (GheOP 3 S)-tool was recently developed as an explicit screening tool to detect drug-related problems (DRPs) and to help in performing medication reviews. In this study, we aimed (a) to describe the characteristics of the detected DRPs and the subsequent pharmacists' recommendations with their acceptance and implementation rate resulting from a pharmacist-led medication review using the GheOP 3 S-tool and (b) to assess the potential impact of the intervention.
leading to an increased risk of drug-related problems (DRPs). 4 A DRP can be defined as an event or circumstance involving medication therapy that actually or potentially interferes with desired health outcomes. 5 DRPs are associated with higher health care utilization (eg, hospitalisations and emergency department visits), reduced quality of life, and increased health care costs. [6] [7] [8] [9] Therefore, health care providers are urged to take action in the prevention of iatrogenic harm related to medications. In this context, the World Health Organization calls for a worldwide commitment to reduce severe and avoidable medication-related harm 10 with 50% by 2022.
Medication review, consisting of a structured evaluation of a patient's pharmacotherapy, has been proposed as a strategy to identify and resolve DRPs. 11 Several studies have shown a positive impact of medication review on the quality of medication use (eg, the number of [appropriate] medications 12, 13 and DRPs 13 ) and on disease-specific outcomes (eg, glycosylated haemoglobin, blood pressure, and cholesterol). 12 However, a forthright effect on major outcomes such as hospitalisation, [12] [13] [14] mortality, 12, 13 health-related quality of life, 14, 15 and health care costs 13, 15 has not yet been demonstrated.
There is an international trend to involve community pharmacists in performing medication reviews, because of their specific medication-related knowledge. However, performing medication reviews is not a common practice in Belgian community pharmacies nor is it reimbursed by the health insurances. To facilitate the detection of DRPs in a structured way and thereby the implementation of medication review in the Belgian community pharmacy practice, we have recently developed the Ghent Older People's Prescriptions community Pharmacy Screening (GheOP 3 S)-tool. 16 This is an explicit screening tool for detecting DRPs with high clinical relevance in community-dwelling older people, without the need for clinical patient data. It was specifically designed for use in the community pharmacy setting. The GheOP So far, we have found that GheOP 3 S-criteria are highly prevalent among older adults with polypharmacy in primary care. [17] [18] [19] However, the acceptance and implementation of pharmacists' recommendations resulting from a multidisciplinary medication review process using the GheOP 3 S-tool have not yet been studied in this population. Therefore, the current study was designed to embed the use of the GheOP DRPs," the anticholinergic and sedative burden, and medication costs.
| METHODS

| Study design, setting, and participants
This study resulted from a collaboration between the Association of Belgian Pharmacies, KU Leuven, Université Libre de Bruxelles, and Ghent University, which was set up to investigate the implementation of pharmacist-led medication reviews in primary care in Belgium. 20 We conducted a prospective observational study from December 2016 to October 2017 in a convenience sample of 12 community pharmacies in Belgium. These pharmacies employed at least one pharmacist who had previously received training in performing medication review using the GheOP 3 S-tool and who was willing to engage in a face-to-face discussion with the GP about the results of the medication review. More than one pharmacist per pharmacy could participate.
Since this was the first time that pharmacists would perform multidisciplinary medication reviews using the GheOP 3 S-tool, the participating pharmacists were asked to search for one or more local GPs who were willing to participate in the study and with whom they had patients in common. The medication review process consisted of six steps:
1. A preparation step including an extraction of the current medication use and previously reported DRPs (eg, allergies, contraindications, and nonadherence) from the electronic pharmacy record.
A pharmacotherapeutic anamnesis:
A face-to-face patient interview at the pharmacy or at the patient's home to:
• Collect basic patient characteristics (age, gender, weight, length, functional status, and self-rated health).
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• Collect smoking status, alcohol use, diet, and cognitive function using the Mini-Cog test.
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• Check the accuracy of the current medication list and potential medication indications.
• Identify experienced ADRs and (practical) problems with medication intake.
• Assess medication adherence and the patient perceived medication effectiveness.
• Discuss the patient's experiences, expectations, and preferences about their medication.
A pharmacotherapeutic analysis consisting of the following:
-Medication screening with the GheOP 3 S-tool to detect "GheOP 3 S-related DRPs". Pharmacists were advised to exclude the GheOP 3 S-criteria concerning direct oral anticoagulants (in light of the emerging evidence 25 ) and to elevate the threshold for the 10-year probability of major osteoporotic fractures from 10% to 20% 26 for the GheOP 3 S-criterion "patient has an elevated risk for osteoporosis and is not prescribed calcium/vitamin D supplementation".
-Identification of "other DRPs" using other sources of information (including DRPs detected during the patient interview).
Additional information (eg, confirmation of diagnosis) could be acquired by contacting the GP or in the next step, the face-to-face discussion with the GP.
-Development of a pharmaceutical care plan with the pharmacist's recommendations to improve medication appropriateness. During the study, pharmacists were supported by the researcher who monthly called them to discuss possible problems or questions and to assess the progress of the study. A financial incentive of 60€
per included patient was provided to the participating pharmacists at the end of the study.
| Data collection
Pharmacists recorded all patient data and interventions in a case report form (CRF) developed by the research team (available upon request). They also recorded for each patient how much time they spent to each step of the intervention.
| Data analysis
All medications were coded using the Anatomical Therapeutic Chemical Classification System (ATC) formulated by the Word Health Organisation Collaborating Centre for Drug Statistics Methodology. 27 All DRPs and pharmacists' recommendations were classified by the researcher and peer reviewed through discussion with a second pharmacist using the Pharmacists' Documentation of Interventions in Seamless Care (PharmDISC) classification system. 28 Primary outcomes were the number and type of DRPs, the subsequent pharmacists' recommendations, and the GPs' acceptance and implementation rate of pharmacists' recommendations. DRPs were categorized as either "GheOP In addition, the potential impact of the intervention was assessed by comparing patient's medication list between baseline (after the patient interview) and 3-month follow-up in terms of the following:
1. The number of medications. 3 | RESULTS
The number of "GheOP
| Sample characteristics
In the 12 participating community pharmacies, 21 pharmacists collaborated with 44 GPs. Eighty-nine patients were invited for study participation, of which 10 (11.2%) refused to participate, resulting in 79 included patients ( Figure 1A ). Four patients were excluded from analysis, resulting in a final sample of 75 patients ( Figure 1A ). Pharmacist and patient characteristics are detailed in Table 1 .
| Intervention characteristics
| Baseline DRPs and resulting pharmacists' recommendations
Pharmacists detected a total of 470 DRPs in 75 patients with a median (IQR) of 6 (4-8) per patient. The most prevalent types of DRPs (according to the PharmDISC classification system) were "contraindication" (19.1%), "interaction" (15.3%), and "missing patient documentation or information" (10.0%) ( Table 2) . Forty-nine percent of DRPs were "GheOP 3 S-related DRPs" (n = 230). Screening with the GheOP 3 S-tool mainly attributed to the detection of DRPs related to overuse/misuse (PharmDISC categories C1.2 contraindication, C1.3 interaction, C4.3 inappropriate therapy duration, and C3.2 overdose, see Table 2 ) and underuse (PharmDISC category C1.1 no concordance with guidelines, only suboptimal therapy possible, Table 2 ). Fifteen GheOP The most common pharmacists' recommendations were to stop medication (22.9%), to substitute medication (18.9%), to monitor therapy (14.5%), and to adjust dose (12.8%) ( Table 2 ). Pharmacists did not record their recommendation for 24 DRPs (5.1%, 24/470) ( Figure 1B1 ).
| Acceptance of pharmacists' recommendations
During the pharmacist-GP meetings, 20 of 446 (4.5%) pharmacists' recommendations were judged as not relevant for the specific patient ( Figure 1B2 ). These were all recommendations for 
| Implementation of pharmacists' recommendations
Overall, 42.9% (183/426, Figure 1B4 ) of pharmacists' recommendations were (fully or partially) implemented at 3-month follow-up. This corresponds to 56.1 % of accepted pharmacists' recommendations. 
| Time investment
The median (IQR) time investment per medication review was 180 The Mini-Cog test consists of three questions: (a) to recall three unrelated words, (b) to draw a clock as a recall distractor, and (c) to recall the three previously unrelated words. Recalling zero words or recalling two or less words and drawing an abnormal clock were suggestive for cognitive impairment. 24 with the GheOP For example, time interval between medication intake (eg, levothyroxine) and food intake.
g For example, instruction of inhaler or eye drop technique.
h For example, addition of missing contraindications or OTC-medications to the patient's electronic pharmacy record.
i The percentage within total number of DRPs.
j The percentage within DRP subtype.
| Potential impact of the intervention
The number of chronic medications had remained unchanged between baseline and 3-month follow-up, while the number of "as needed"
medications had slightly decreased (P = .002) (Appendix S2). At 3-month follow-up, the number of "GheOP 3 S-related DRPs" (P < .001) significantly decreased (Appendix S2). Furthermore, the DBI score was slightly lower at follow-up (versus baseline) (P = .033), but the medication costs had remained unchanged (Appendix S2).
| DISCUSSION
In this study, we investigated a community pharmacist-led medication review process (including a face-to-face meeting with both the patient and the GP) in older patients with polypharmacy using the GheOP Our study showed a relatively high (67%) overall acceptance rate of pharmacists' recommendations. This is in accordance with other studies investigating pharmacist-led medication reviews 34, 35 and demonstrates that GPs were indeed (this was an inclusion criterion) willing to collaborate during the face-to-face meetings. Less challenging recommendations (eg, optimization of administration, start medication, and therapy monitoring) were most likely to be accepted. In most cases of nonacceptance, the GP perceived that the medication needed to be continued or that the recommendation was currently of inferior priority. Although we did not investigate the clinical relevance of these recommendations, a possible explanation for not accepting certain recommendations could be "inertia. Implementation is higher than acceptance due to recommendations that were not accepted, but implemented; or recommendations of which the acceptance was not recorded that were nonetheless implemented.
Abbreviations: DRP, drug-related problem; PharmDISC, Pharmacists' Documentation of Interventions in Seamless Care.
message towards the patient. Accordingly, more intensive collaboration between pharmacist and GP to reinforce trust and their professional relationship could lead to higher acceptance and implementation rates. 37 In addition, introducing extra follow-up moments could increase the actual implementation of interventions that were postponed.
About half of the detected DRPs were related to GheOP 3 S-criteria.
Most prevalent GheOP 3 S-criteria comprised the overuse or misuse of potentially inappropriate medications and underuse. Most frequently involved medications were benzodiazepines, antidepressants, calcium/vitamin D, PPIs, and anticholinergics, which is also regularly reported in other studies. 41, 42 Pharmacists also detected a large number of "other DRPs" (51%), which consisted of a variety of DRP types.
Prevalent "other DRPs" encompassed DRPs such as "missing patient documentation or information" (eg, untreated symptoms or medications not present in the electronic pharmacy record), "adverse effect,"
and "financial burden." These types of DRPs cannot be detected by merely screening a medication list with the help of an explicit screening tool. Patient involvement by including a patient interview in the medication review process is a key factor to detect these additional types of DRPs. 43, 44 This is supported by our finding that 26% of all detected DRPs were only detected on the basis of the patient interview. Notwithstanding the different types of "GheOP 3 S-related DRPs"
and "other DRPs," the acceptance and implementation rate of pharmacists' recommendations for both types of DRPs were similar.
An essential factor that needs to be tackled to implement medication reviews on a larger scale is the considerable time investment.
Pharmacists reported a median of 180 minutes to complete the whole review, which has also been reported in literature on pharmacist-led medication reviews. 45 Our study has several strengths. First, this is the first study exploring the use and potential impact of the GheOP 3 S-tool during a multidisciplinary medication review in an ambulatory primary care setting.
Second, this study combined the use of an explicit screening tool, the GheOP 3 S-tool, with a patient-centred approach (eg, including patient interviews) to detect additional DRPs.
Although the results of the present study are promising, there are some limitations that should be taken into account. First, participating pharmacists were presumably more motivated as most of them volunteered to participate (participation bias). Pharmacists probably selected GPs who were more likely to engage in a pharmacist-GP collaboration and patients of whom they thought could benefit from a medication review (selection bias). This could have led to higher acceptance rates and could limit the generalizability. Second, the observational design of this study could only detect a "potential" impact of the intervention on different outcomes. In addition, we were not able to assess medication appropriateness or clinical relevance of pharmacists' recommendations due to incomplete data. Noteworthy, the detection of DRPs in this study was primarily based on data from the electronic pharmacy record (eg, dispensed medications, certain contraindications, and allergies) and from the patient interview (eg, the actual medication use and problems and experiences with medications). Pharmacists could contact the GP for additional information during the pharmacotherapeutic analysis, but they had no access to the GP's medical records. In addition, studies investigating medication review processes often have different designs and settings, which hinder a forthright comparison in acceptance and implementation of pharmacists' recommendations.
Future larger sampled (longer-term) studies should determine the impact of this medication review process on patient-centred outcomes. A full cost-effectiveness analysis should also be performed in the future.
| CONCLUSION
This study demonstrates that a multidisciplinary pharmacist-led medication review including a patient interview, screening with the GheOP 3 S-tool and face-to-face pharmacist-GP meetings detects a high number of DRPs. The acceptance rate of pharmacists' recommendations was relatively high, although this did not translate into a similar implementation rate. At follow-up, the number of "GheOP 3 S-related DRPs" and the anticholinergic and sedative burden of patients were reduced, which illustrates the potential positive impact of pharmacists performing medication reviews in collaboration with GPs. Future studies should focus on higher-risk patients to efficiently allocate time, ensure patient involvement (shared decision making), and collaboration between pharmacists and GPs to establish trust and streamline information.
